Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Studies with bromocriptine. Part 1. "On-off" phenomena

R Kartznel, D B Calne

    Neurology
    |June 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Bromocriptine, a dopaminergic agonist, reduced the frequency of "on-off" phenomena in Parkinson's disease patients. However, bromocriptine itself can induce these fluctuations, suggesting complex mechanisms beyond levodopa pharmacokinetics.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The cardiovascular effects of bromocriptine in Parkinsonism.

    British journal of clinical pharmacology·2012
    Same author

    Parkinsonism-physiology and pharmacology.

    British medical journal·2010
    Same author

    German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia - Longitudinal observations.

    Parkinsonism & related disorders·2008
    Same author

    The role of the Lewy body in idiopathic Parkinsonism.

    Parkinsonism & related disorders·2008
    Same author

    The natural history of neurological manganism over 18 years.

    Parkinsonism & related disorders·2006
    Same author

    Autosomal dominant dystonia-plus with cerebral calcifications.

    Neurology·2006

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Movement Disorders

    Background:

    • Idiopathic Parkinson's disease is often complicated by severe motor fluctuations, known as "on-off" phenomena, particularly with levodopa treatment.
    • Levodopa remains a cornerstone therapy, but its efficacy can be limited by unpredictable swings between motor symptom control and disability.

    Purpose of the Study:

    • To evaluate the efficacy of bromocriptine, a dopaminergic agonist, in managing "on-off" phenomena in patients with idiopathic parkinsonism.
    • To compare the frequency and severity of motor fluctuations when patients were treated with levodopa versus bromocriptine.

    Main Methods:

    • A blinded, within-patient, self-evaluating study design was employed.
    • Patients with idiopathic parkinsonism experiencing "on-off" phenomena were switched from levodopa (with or without carbidopa) to bromocriptine.

    Related Experiment Videos

    Main Results:

    • While bromocriptine significantly reduced the frequency of "on-off" phenomena compared to levodopa, these fluctuations were not entirely eliminated.
    • Bromocriptine was also observed to induce "on-off" phenomena in some patients, complicating direct comparisons.

    Conclusions:

    • Bromocriptine offers a potential therapeutic option for reducing levodopa-induced "on-off" phenomena in Parkinson's disease.
    • The occurrence of "on-off" phenomena with bromocriptine suggests that factors beyond levodopa pharmacokinetics, such as receptor sensitivity or unidentified neurophysiologic mechanisms, may play a role.